Journal of pharmaceutical analysis最新文献

{"title":"Multicomponent coordination-driven self-assembled metallacycles as efficient photosensitizers for photodynamic therapy.","authors":"Jinping Zhang, Yali Hou, Qian Feng, Dengke Han, Qi Sun, Yuling Wu, Sida Liu, Dong Liu, Fei Xue, Jin Zhang, Jianing Wang, Xianglong Duan, Feng Liu, Mingming Zhang","doi":"10.1016/j.jpha.2026.101644","DOIUrl":"https://doi.org/10.1016/j.jpha.2026.101644","url":null,"abstract":"<p><p>Novel TPE-based metallacycles were developed as efficient supramolecular photosensitizers, offering new opportunities for optimizing photodynamic therapy and advancing its biomedical applications.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 8","pages":"101644"},"PeriodicalIF":8.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13485630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148804395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active peptides pursuit from complicated matrices via tracing ligand-protein complex with MS/MS: Chaperone screening for lysozyme as a pilot study.","authors":"Zihan Zhu, Jiahui Wen, Ting Li, Han Li, Wei Li, Ke Zhang, Pengfei Tu, Wenjing Liu, Yuelin Song","doi":"10.1016/j.jpha.2026.101586","DOIUrl":"10.1016/j.jpha.2026.101586","url":null,"abstract":"<p><p>Image 1.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101586"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13382026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning for small-molecule drug discovery: From molecular design to clinical translation.","authors":"Rita I Oliveira, Tiago O Pereira, Maryam Abbasi, Jorge A R Salvador, Joel P Arrais","doi":"10.1016/j.jpha.2025.101533","DOIUrl":"10.1016/j.jpha.2025.101533","url":null,"abstract":"<p><p>Recent advances in artificial intelligence (AI) are increasingly transforming drug discovery, offering new approaches to accelerate the identification and optimization of therapeutic candidates. Deep learning (DL) methods have shown strong potential for generative modeling and molecular property prediction, enabling the design of compounds with tailored pharmacological profiles. In this review, we synthesize recent AI-driven progress in drug discovery, highlighting both achievements and ongoing challenges. We discuss key technical aspects underpinning DL-based models, including the use of curated molecular databases, molecular descriptors, and standardized evaluation strategies. We examine representative architectures and illustrate how they have been applied to molecular generation, binding affinity prediction, and multi-modal integration of ligand and protein data. In addition, we provide a comprehensive analysis of AI-enabled small-molecule drugs, including discovered and repurposed molecules in clinical trials, and explore the intellectual property information and chemical structures of these compounds. We demonstrate that AI-native companies are evolving pharmaceutical pipelines by integrating these tools at various stages of development. We also address the regulatory framework of agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as they adapt to integrate AI innovations. Finally, we outline persistent limitations, such as data inconsistency, model interpretability, and the gap between benchmark performance and real-world applicability, which remain critical barriers to widespread adoption. By consolidating technical advances and open challenges, this review aims to provide a balanced perspective on the role of AI in reshaping modern drug discovery.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101533"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13375945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic repurposing of old drugs to modulate the tumor immune microenvironment and enhance immunotherapy efficacy.","authors":"Yakai Song, Nannan Zheng, Xu Yang, Zhaofan Tao, Qinghui Wang, Zhiyue Cao, Yi Zhang, Mengmeng Li, Ruixin Mao, Yuhao Chen, Chen Zhao, Huanjie Yang, Bin Yang, Qiuyue Ma, Liangcan He, Shaoqin Liu, Kai Li","doi":"10.1016/j.jpha.2025.101510","DOIUrl":"10.1016/j.jpha.2025.101510","url":null,"abstract":"<p><p>Although immunotherapy has demonstrated remarkable progress in cancer treatment, its clinical benefits remain restricted to a subset of patients and specific cancer types, primarily due to the immunosuppressive nature of the tumor microenvironment (TME) in solid tumors. Therefore, many strategies have focused on targeting the immunosuppressive TME to enhance immune-mediated tumor eradication. In parallel, the repositioning of old drugs represents an attractive discovery approach compared with the traditional <i>de novo</i> drug discovery process, which is time-consuming and costly. Thus, repurposing US Food and Drug Administration (FDA)-approved old drugs to modulate the tumor immune microenvironment represents a promising strategy to augment the effectiveness of cancer immunotherapy. Indeed, emerging evidence indicates that several approved drugs can reprogram the tumor immune landscape, thereby enhancing responses to immunotherapy. This review provides a comprehensive overview of US FDA-approved old drugs with immunomodulatory properties in the tumor context. We discuss their mechanisms in reversing immunosuppression, summarize key findings from preclinical studies and clinical trials involving their combination with immunotherapies, and outline future perspectives for their clinical translation. Collectively, this work highlights the translational potential of drug repurposing as a strategy to expand the therapeutic reach of cancer immunotherapy.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101510"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13382183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug delivery system of curcumin to the lungs based on poly(3-alloxyloxy-1,2-propylene succinate)-sebacic acid copolymers.","authors":"Karolina Knap, Konrad Kwiecień, Jonasz Czajkowski, Rafał Szostecki, Daria Niewolik, Katarzyna Jaszcz, Peter Olinga, Katarzyna Reczyńska-Kolman, Elżbieta Pamuła","doi":"10.1016/j.jpha.2025.101434","DOIUrl":"10.1016/j.jpha.2025.101434","url":null,"abstract":"<p><p>Polyanhydrides are attractive materials for drug delivery matrices as a result of their cytocompatibility and fast degradation rate. Here, we synthesized and characterized copolymers of poly(3-allyloxy-1,2-propylene succinate) (PSAGE) and sebacic acid (SBA). The successful polymerization was confirmed by proton nuclear magnetic resonance (¹H NMR) and Fourier transform infrared (FTIR) spectroscopy analyses. The material with PSAGE and 60% of SBA copolymer (PSAGE-SBA60) was more hydrophilic than the PSAGE and 80% of SBA copolymer (PSAGE-SBA80) (water contact angle 82.2° ± 11.6° vs. 98.6° ± 8.9°, respectively). PSAGE-SBA60 also had a lower molecular weight than PSAGE-SBA80 (M_n = 6400 Da vs. 9800 Da). Both polyanhydrides were used to encapsulate curcumin (CUR) as a potential anti-inflammatory, antimicrobial and anticancer agent. The unloaded microparticles (MPs) and CUR-loaded MPs were produced using the emulsification/solvent evaporation method. The CUR was uniformly distributed within the MPs, as confirmed by fluorescence microscopy. All MPs had a geometric diameter < 5 μm and their surface charge was negative. MPs_PSAGE-SBA80 + CUR had the best aerodynamic properties, as shown by laser diffraction measurements and flowability parameters, i.e., Carr index and Hausner ratio. The MPs obtained from PSAGE-SBA60 degraded faster than those of PSAGE-SBA80. All MPs were noncytotoxic at a concentration of up to 100 μg/mL in the <i>in vitro</i> model (BEAS-2B lung epithelial cells) and <i>ex vivo</i> precision-cut tissue slices (PCTSs) rat model. The developed MPs are promising CUR carriers for pulmonary delivery in a dry powder formulation.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101434"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13400944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148595485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nanotechnology-enhanced SERS platform integrated with isothermal amplification for ultrasensitive detection of urinary miR-21 in early acute kidney injury diagnosis.","authors":"Liangping Fan, Wenna Liu, Qian Li, Jixue Lu, Fengchi Jiang, Qi Yan, Xiaoyan Liu, Jie Wang","doi":"10.1016/j.jpha.2026.101585","DOIUrl":"10.1016/j.jpha.2026.101585","url":null,"abstract":"<p><p>Acute kidney injury (AKI) remains a critical clinical condition with high morbidity and mortality, underscoring the urgent need for early and accurate diagnostic tools. Traditional biomarkers such as serum creatinine (Cr) and blood urea nitrogen (BUN) suffer from delayed response and lack of specificity, limiting their utility in early-stage AKI detection. This study presents an innovative nanotechnology-enabled platform combining isothermal nucleic acid amplification with surface-enhanced Raman spectroscopy (SERS) for the direct and ultrasensitive detection of urinary microRNA-21 (miR-21), a promising early biomarker for AKI. The platform leverages a cascade signal amplification strategy: (1) a polymerase/endonuclease-mediated isothermal amplification system for target recognition and primer generation, (2) a hybridization chain reaction (HCR) to self-assemble DNA nanostructures conjugated with gold nanostars core with silver shell and 4-aminothiophenol (AuNS/Ag@4-ATP) SERS nanoprobes, and (3) a polyadenine-functionalized SERS substrate for robust signal capture. This integrated approach achieves a remarkable detection limit of 8.4 femtomolar (fM), surpassing conventional methods like quantitative reverse transcription polymerase chain reaction (qRT-PCR) in sensitivity while eliminating the need for RNA extraction or thermocycling. Clinical validation using patient urine samples demonstrated the platform's ability to detect miR-21 elevations 24-48 h earlier than traditional biomarkers, with exceptional specificity and reproducibility (relative standard deviation (RSD) < 5.7%). The modular design and direct urine compatibility highlight its potential for point-of-care applications, offering a rapid (<2 h) and equipment-minimized solution for early AKI diagnosis. This work not only advances AKI biomarker detection but also provides an adaptable framework for other disease-related nucleic acid analyses, bridging nanotechnology with clinical diagnostics.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101585"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13382247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential mechanisms of natural products in improving gouty arthritis: Focusing on NLRP3 inflammasome regulation.","authors":"Yunhao Yi, Yanling Chen, Wuchaonan Liu, Jingjing Yang, Le Yang, Jing Liu, Shengping Luo, Qianru Zeng, Tao Gao, Yihui Deng","doi":"10.1016/j.jpha.2026.101563","DOIUrl":"10.1016/j.jpha.2026.101563","url":null,"abstract":"<p><p>Gouty arthritis (GA) is a metabolic inflammatory disorder characterized by the deposition of monosodium urate crystals. Although conventional treatments like colchicine can relieve symptoms, they come with several limitations, such as gastrointestinal side effects, hepatorenal toxicity, and poor target specificity. In contrast, natural products, known for their multi-pathway and multi-target properties, present distinct advantages and significant potential for intervening in GA. The primary pathological mechanism of GA involves the overactivation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, making its regulation a promising therapeutic approach. However, there is currently a lack of comprehensive reviews on how natural products target the NLRP3 inflammasome. Additionally, existing studies have not sufficiently classified or integrated the mechanisms involved in transcriptional and translational regulation during the priming phase, post-translational modifications, and the various pathways active during the activation phase. This article aims to address these gaps through a systematic literature review, providing an in-depth analysis of the molecular mechanisms by which natural products alleviate GA by targeting the NLRP3 inflammasome. It also critically examines the major challenges in current translational research, with the objective of offering a solid theoretical foundation and practical strategies for developing novel, effective anti-inflammatory drugs and expediting the clinical application of natural products for GA treatment.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101563"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13400883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148595448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synovial microenvironment and fluorescence imaging for early rheumatoid arthritis diagnosis.","authors":"Hua Wang, Pan Zhou, Huixiang Chen, Jiachen Zheng, Linlin Wei, Jiabin Chen, Yu Lei","doi":"10.1016/j.jpha.2025.101509","DOIUrl":"10.1016/j.jpha.2025.101509","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that primarily affects the joints and surrounding soft tissues. Early diagnosis is crucial for preventing joint damage and improving the prognosis and quality of life in RA patients. Therefore, this article reviews conventional diagnostic methods, such as serologic tests (including rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA), and anti-carbamylated protein (anti-CarP)) and imaging tests and also focuses on innovations in AI-driven diagnostic and therapeutic technologies. Additionally, we provide insights into new biomarkers (including macrophages, neutrophils, and synovial fibroblasts) in the synovial microenvironment that correlate with RA disease activity and severity at the molecular level. Importantly, we are optimistic about fluorescence imaging (FOI) techniques (including visible light imaging and near-infrared (NIR)-FOI), which can accurately quantify abnormal levels of molecular markers using fluorescent probes. This provides detailed information about pathological changes in RA, opening new horizons for early diagnosis and treatment.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101509"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13400947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148595478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in proteomic strategies for target identification of traditional Chinese medicine.","authors":"Xueyan Zhen, Jingwen Liu, Yan Ren","doi":"10.1016/j.jpha.2025.101516","DOIUrl":"10.1016/j.jpha.2025.101516","url":null,"abstract":"<p><p>Traditional Chinese medicine (TCM) has played an indispensable role in health intervention and disease treatment. Identifying the target proteins of TCM is crucial to clarifying therapeutic mechanisms. One approach taken to enhance the breadth, depth, and precision of studies on the active cellular pathways induced by TCM is to use proteomics to reveal potential drug targets with direct interactions. Proteomic strategies facilitate identifying and characterizing target binding proteins relevant to metabolic pathways, which involves enriching the complex of small molecule and their targets based on the affinity, as well as utilizing the changes in physicochemical properties of target proteins that occur due to drug binding for proteomic identification and quantification. Probe labeling and enrichment technologies have accelerated the field of chemical proteomics. Technologies focused on measuring the changes in target proteins have been widely extended into several different approaches, and these now drive the establishment of further strategies. This review summarizes the advances in proteomics strategies mainly based on mass spectrometry (MS) for the identification of TCM targets to the present. Enhancing the application of proteomics would provide a new viewpoint on TCM treatment, while underscores the potential of TCM as biological probes and sources of novel drug candidates.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101516"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13377450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iontophoresis-assisted transdermal drug delivery for the treatment of inflammatory dermatoses: A review.","authors":"Zhixiong Wang, Xiumei Jiang, Changzhao Jiang, Xiaohua Tao, Jincui Ye","doi":"10.1016/j.jpha.2025.101512","DOIUrl":"10.1016/j.jpha.2025.101512","url":null,"abstract":"<p><p>Inflammatory dermatoses, including psoriasis, atopic dermatitis (AD), and acne vulgaris, pose significant challenges in dermatological treatment due to the skin's natural barrier, the stratum corneum (SC), which limits the efficacy of topical formulations. Iontophoresis, a non-invasive technique that applies low-level electrical currents to enhance transdermal drug delivery, has emerged as a promising solution to overcome these barriers. This review explores the application of iontophoresis-assisted drug delivery for treating inflammatory skin conditions, focusing on its mechanisms, benefits, and potential for combination with existing topical formulations. Iontophoresis enhances the penetration of both small molecules, such as corticosteroids, and biological macromolecules, including monoclonal antibodies and nucleic acid-based therapies, into deeper skin layers. This optimized therapeutic delivery maximizes localized efficacy while minimizing systemic exposure and potential adverse effects. Furthermore, when combined with other transdermal enhancement techniques such as microneedles and sonophoresis, iontophoresis demonstrates synergistic effects, facilitating the delivery of challenging drug molecules and enabling controlled, targeted release. Recent advances in wearable iontophoresis devices present new opportunities for continuous and patient-friendly drug administration, particularly for chronic conditions requiring long-term management. Despite these advantages, challenges such as variability in skin response, potential irritation, and device costs remain. Further research and technological advancements are needed to optimize iontophoresis systems for broader clinical applications. Overall, this review highlights the versatility and prospects of iontophoresis as an innovative therapeutic approach in managing inflammatory dermatoses.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"16 7","pages":"101512"},"PeriodicalIF":8.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13382289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}